PureTech公布的2b期开放标签扩展数据显示，德匹非尼酮稳定了Fiberfenidone患者的肺功能，耐受性良好

Patients who switched from placebo or pirfenidone to deupirfenidone in the open-label extension study achieved stabilization of lung function with favorable tolerability

Findings further substantiate safety and efficacy results from the randomized, placebo- and active-controlled 26-week trial and highlight opportunity to address patients inadequately served by current therapies

Regulatory engagement underway; update on Phase 3 trial design expected in Q4 2025